Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SERGIO F ROVNER

Allopathic & Osteopathic Physicians Internal Medicine Endocrinology, Diabetes & Metabolism

NPI
1437164803
CMS profile
64313
Location
EL PASO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$92,309.19

406 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Page 7 of 9; records 301–350 of 406 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SERGIO F ROVNER

NPI 1437164803 · CMS profile ID 64313

Allopathic & Osteopathic Physicians / Internal Medicine / Endocrinology, Diabetes & Metabolism

EL PASO, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 7 of 9; records 301–350 of 406 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1437164803?year=2022&recipient=provider&page=7#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SERGIO F ROVNER, NPI 1437164803, CMS profile ID 64313. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 7 of 9; records 301–350 of 406 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1437164803?year=2022&recipient=provider&page=7#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). SERGIO F ROVNER, NPI 1437164803, CMS profile ID 64313. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 7 of 9; records 301–350 of 406 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1437164803?year=2022&recipient=provider&page=7#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
SERGIO F ROVNER, NPI 1437164803, CMS profile ID 64313, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 7 of 9; records 301–350 of 406 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1437164803?year=2022&recipient=provider&page=7#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

406 matching records · $92,309.19 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 406 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 301–350 of 406.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novo Nordisk Inc $250.1704/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898574563 CMS
Novo Nordisk Inc $91.3404/09/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898844307 CMS
Novo Nordisk Inc $262.0104/09/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898940915 CMS
Novo Nordisk Inc $508.8004/09/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 899134477 CMS
Novo Nordisk Inc $4,700.5004/09/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 899327493 CMS
Medtronic, Inc. $9.4004/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930717711 CMS
Horizon Therapeutics plc $12.8504/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937684183 CMS
Lilly USA, LLC $650.0004/07/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918299807 CMS
Lilly USA, LLC $500.0004/07/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918299809 CMS
Lilly USA, LLC $975.0004/07/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918366739 CMS
Novo Nordisk Inc $2,210.0004/07/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898572405 CMS
Novo Nordisk Inc $89.4304/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898940907 CMS
AstraZeneca Pharmaceuticals LP $15.9004/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920258625 CMS
Radius Health, Inc. $11.3404/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954939833 CMS
Medtronic, Inc. $100.0304/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930717713 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $15.7804/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 960009189 CMS
Amgen Inc. $23.7603/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939811849 CMS
Amarin Pharma Inc. $24.4403/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 913962261 CMS
Lilly USA, LLC $17.7003/30/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918346083 CMS
Novo Nordisk Inc $24.6203/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898574653 CMS
Abbott Laboratories $24.4803/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920492298 CMS
Novo Nordisk Inc $10.2503/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898574641 CMS
Novo Nordisk Inc $6.2203/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898844268 CMS
Amgen Inc. $21.6003/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939811893 CMS
RECORDATI_RARE_DISEASES_INC. $0.7203/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 961612651 CMS
RECORDATI_RARE_DISEASES_INC. $10.0603/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 961612655 CMS
Corcept Therapeutics $4,000.0003/21/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 948798983 CMS
Novartis Pharmaceuticals Corporation $13.8603/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894301513 CMS
Lilly USA, LLC $463.6703/18/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918330059 CMS
Medtronic, Inc. $9.9703/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 930717715 CMS
AstraZeneca Pharmaceuticals LP $13.1603/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920259539 CMS
Novo Nordisk Inc $15.4303/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 899410133 CMS
ABBVIE INC. $9.9103/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891486149 CMS
Lilly USA, LLC $650.0003/11/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918330063 CMS
Lilly USA, LLC $650.0003/11/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918366737 CMS
Novo Nordisk Inc $0.8303/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898647221 CMS
Novo Nordisk Inc $5.8303/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898665799 CMS
Corcept Therapeutics $27.6803/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 948798951 CMS
AstraZeneca Pharmaceuticals LP $93.3803/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920240877 CMS
Biohaven Pharmaceutical Holding Company Ltd. $15.8503/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923717615 CMS
Insulet Corporation $23.1503/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 933139191 CMS
ABBVIE INC. $13.2503/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891486147 CMS
Amarin Pharma Inc. $21.0403/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 913962265 CMS
Lilly USA, LLC $24.7703/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918282145 CMS
Novo Nordisk Inc $19.3403/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898891193 CMS
Biohaven Pharmaceutical Holding Company Ltd. $16.3003/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 923717613 CMS
Horizon Therapeutics plc $6.9003/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937684181 CMS
Novo Nordisk Inc $3.4003/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 899085095 CMS
PFIZER INC. $16.2902/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949063667 CMS
Amgen Inc. $19.7002/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939811889 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $141,407.43 433
PY2020 $61,521.92 284
PY2021 $59,905.34 322
PY2022 $92,309.19 406
PY2023 $90,014.02 360
PY2024 $98,213.87 418
PY2025 $102,323.66 387

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $545,298.45 24
PY2024 Recipient $1,586.84 12
PY2024 Principal investigator $250,628.60 22
PY2023 Principal investigator $89,757.57 112
PY2022 Principal investigator $165,647.84 46
PY2021 Recipient $849.27 1
PY2021 Principal investigator $285,644.51 124
PY2020 Recipient $836.34 1
PY2020 Principal investigator $539,614.00 212
PY2019 Recipient $615.75 1
PY2019 Principal investigator $334,189.33 76

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

24 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $6,100.00 12/31/2025 Non-covered Recipient Entity
FRONTIER MEDICAL CENTER
A Phase 2/3 multicenter, double blinded, randomized, dose-conversion, active control study examining the efficacy and safety of Armour Thyroid compared to synthetic T4 for the treatment of adults with primary hypothyroidism No dispute reported 06/30/2026 1202532602
Principal investigator 1 ABBVIE INC. $12,637.20 12/05/2025 Non-covered Recipient Entity
ACADEMY OF DIABETES THYROID
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202529276
Principal investigator 1 Alnylam Pharmaceuticals Inc. $1,735.29 12/01/2025 Non-covered Recipient Entity
Academy of Diabetes, Thyroid and Endocrine, P.A.
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215524592
Principal investigator 1 ABBVIE INC. $213,870.96 11/05/2025 Non-covered Recipient Entity
ACADEMY OF DIABETES THYROID
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202522461
Principal investigator 1 Boehringer Ingelheim International GmbH $6,300.00 10/22/2025 Non-covered Recipient Entity
ACDMY OF DIABETES THYROID AND ENDOCRINE, PA
A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease No dispute reported 06/30/2026 1220776579
Principal investigator 1 Alnylam Pharmaceuticals Inc. $771.03 10/21/2025 Non-covered Recipient Entity
Academy of Diabetes, Thyroid and Endocrine, P.A.
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215524594
Principal investigator 1 AstraZeneca Pharmaceuticals LP $33,715.70 09/26/2025 Non-covered Recipient Entity
ACADEMY OF DIABETES THYROID AND ENDOCRINE, PA
A Phase IIb Randomized Double blind Placebo controlled and Open label Active Comparator Study to Evaluate the Efficacy Safety and Tolerability of AZD5004 in Adults with Type 2 Diabetes Mellitus No dispute reported 06/30/2026 1185550213
Principal investigator 1 Alexion Pharmaceuticals, Inc. $3,998.70 09/03/2025 Non-covered Recipient Entity
ACADEMY OF DIABETES THYROID AND ENDOCRINE, PA
Eneboparatide - Calypso study which is a pivotal phase 3 study investigational therapeutic peptide with a novel mechanism of action for hypoparathyroidism No dispute reported 06/30/2026 1185550209
Principal investigator 1 Alnylam Pharmaceuticals Inc. $2,339.24 07/15/2025 Non-covered Recipient Entity
Academy of Diabetes, Thyroid and Endocrine, P.A.
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215524568
Principal investigator 1 ABBVIE INC. $27,768.48 07/02/2025 Non-covered Recipient Entity
ACADEMY OF DIABETES THYROID
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202494939
Principal investigator 1 Amgen Inc. $5,657.16 06/11/2025 Non-covered Recipient Entity
ACADEMY OF DIABETES, THYROID AND ENDOCRINE, P.A.
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity No dispute reported 06/30/2026 1246638684
Principal investigator 1 ABBVIE INC. $57,835.68 06/03/2025 Non-covered Recipient Entity
ACADEMY OF DIABETES THYROID
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202487345
Principal investigator 1 ABBVIE INC. $34,837.68 05/07/2025 Non-covered Recipient Entity
ACADEMY OF DIABETES THYROID
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202482841
Principal investigator 1 Alnylam Pharmaceuticals Inc. $3,436.70 04/17/2025 Non-covered Recipient Entity
ACADEMY OF DIABETES, THYROID AND ENDOCRINE, P.A.
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215520273
Principal investigator 1 ABBVIE INC. $13,043.28 04/03/2025 Non-covered Recipient Entity
ACADEMY OF DIABETES THYROID
A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202469800
Principal investigator 1 Boehringer Ingelheim International GmbH $1,500.00 03/12/2025 Non-covered Recipient Entity
ACDMY OF DIABETES THYROID AND ENDOCRINE, PA
A multicenter, international, randomized, double-blind, placebo-controlled clinical trial of the aldosterone synthase inhibitor BI 690517 in combination with empagliflozin in patients with chronic kidney disease No dispute reported 06/30/2026 1220776577
Principal investigator 1 ABBVIE INC. $32,920.56 03/07/2025 Non-covered Recipient Entity
ACADEMY OF DIABETES THYROID
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202459600
Principal investigator 1 Alexion Pharmaceuticals, Inc. $5,235.30 03/06/2025 Non-covered Recipient Entity
UNIVERSITY MEDICAL CENTER OF EL PASO
Eneboparatide - Calypso study which is a pivotal phase 3 study investigational therapeutic peptide with a novel mechanism of action for hypoparathyroidism No dispute reported 06/30/2026 1185550211
Principal investigator 1 Alnylam Pharmaceuticals Inc. $7,550.60 02/20/2025 Non-covered Recipient Entity
ACADEMY OF DIABETES, THYROID AND ENDOCRINE, P.A.
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215520221
Principal investigator 1 Alnylam Pharmaceuticals Inc. $8,149.46 02/20/2025 Non-covered Recipient Entity
ACADEMY OF DIABETES, THYROID AND ENDOCRINE, P.A.
Zilebesiran as Add-on Therapy in Patients With High Cardiovascular Risk and Hypertension Not Adequately Controlled by Standard of Care Antihypertensive Medications (KARDIA-3) No dispute reported 06/30/2026 1215520224
Principal investigator 1 ABBVIE INC. $18,075.84 02/06/2025 Non-covered Recipient Entity
ACADEMY OF DIABETES THYROID
M21-341 - A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants No dispute reported 06/30/2026 1202448145
Principal investigator 1 Eli Lilly and Company $1,253.59 01/27/2025 Non-covered Recipient Entity
ACADEMY OF DIABETES THYROID & ENDOCRINE
THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) No dispute reported 06/30/2026 1187873193
Principal investigator 1 Eli Lilly and Company $45,566.00 01/21/2025 Non-covered Recipient Entity
ACADEMY OF DIABETES THYROID & ENDOCRINE
THE EFFECT OF TIRZEPATIDE VERSUS DULAGLUTIDE ON MAJOR ADVERSE CARDIOVASCULAR EVENTS IN PATIENTS WITH TYPE 2 DIABETES (SURPASS CVOT) No dispute reported 06/30/2026 1187875735
Principal investigator 1 Boehringer Ingelheim International GmbH $1,000.00 01/13/2025 Non-covered Recipient Entity
ACDMY OF DIABETES THYROID AND ENDOCRINE, PA
EMPA-KIDNEY No dispute reported 06/30/2026 1220776575